Pfizer
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, Pfizer sits in the top decile of US sponsors by registered trial count (#7 of 15,742 sponsors by registered trial count).
Pfizer: 1,845 sponsored US clinical trials, 106 recruiting.
Pfizer sponsors 1,845 registered US clinical trials on ClinicalTrials.gov, 106 of them currently recruiting, and 1,335 completed. 504 of these trials are in Phase 3-4 (later-stage) and 1,173 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Healthy, with 44 trials.
Top-decile sponsor footprint
Pfizer ranks in the top decile of sponsors by registered trial count (#7 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
1,335 of 1,673 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (79.8%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Open and recent trials
1,845 total, page 9 of 37
A 12-week Titrate Study TO Evaluate Safety, Tolerability AND Pharmacodynamics OF PF-06882961 IN Adults With Type 2 Diabetes Mellitus AND IN Non-diabetic Adults With Obesity
NCT04617275
Study OF PF-06882961 IN Participants With AND Without Varying Degrees OF Hepatic Impairement
NCT04604496
Global Prevalence of ATTR-CM in Participants With HFpEF
NCT04424914
Efficacy, Safety, and Tolerability of ATM-AVI in the Treatment of Serious Infection Due to MBL-producing Gram-negative Bacteria
NCT03580044
A Bioequivalence Study Between the Proposed and Current Talazoparib Capsule Formulation and Food Effect Study for the Proposed Talazoparib Capsule Formulation in Participants With Advanced Solid Tumors
NCT04672460
Study To Assess Efficacy, Safety, Tolerability And Pharmacokinetics Of PF-07038124 Ointment In Participants With Atopic Dermatitis Or Plaque Psoriasis
NCT04664153
Actigraphy Improvement With Voxelotor (ActIVe) Study
NCT04400487
Estimation of the Effect of Multiple Dose Ritlecitinib (PF-06651600) on the Pharmacokinetics of a Single Dose of Caffeine in Healthy Participants
NCT04655040
Study to Test the Safety and Tolerability of PF-07209960 in Advanced or Metastatic Solid Tumors
NCT04628780
A Study to Assess the Safety and Efficacy of Oral Etrasimod in Adult Participants With Eosinophilic Esophagitis
NCT04682639
Study To Evaluate The Effect Of Two Steady State Doses of PF 06882961 On Rosuvastatin And Midazolam Pharmacokinetics In Otherwise Healthy Adult Participants With Obesity
NCT04621227
Study to Evaluate Safety and Tolerability of PF-07242813 in Healthy Participants and Participants With Atopic Dermatitis
NCT04668066
A Study to Evaluate GBT021601 in Single and Multiple Doses in Healthy Participants
NCT05036512
Safety and Immunogenicity Study of 20vPnC in Healthy Children 15 Months Through 17 Years of Age
NCT04642079
A Study Of Safety, Tolerability And Effectiveness Of Recifercept In Children With Achondroplasia
NCT04638153
Study to Assess the Safety and Tolerability of Repeated Doses of an Investigational New Drug in Patients With Cancer and Cachexia.
NCT04299048
Study to Evaluate the Effect of GBT440 on TCD in Pediatrics With Sickle Cell Disease
NCT04218084
Study of Immunotherapy (Sasanlimab) in Combination With Targeted Therapies in People With Advanced Non-small Cell Lung Cancer (NSCLC) (Landscape 1011 Study)
NCT04585815
Effectiveness And Safety Of Oral Anticoagulants Among Obese Patients With Non-Valvular A-Fib In VA Patients With Medicare
NCT04681482
Randomized Trial in Adult Participants With Acute Migraines
NCT04571060
Single Ascending Dose Study of Intravenous Infusion of PF 07304814 in Healthy Adult Participants
NCT04627532
Bioavailability Study of Naloxone 5 Milligrams (mg) Intramuscular (IM) Autoinjector
NCT05264493
Clinical Study to Evaluate Pharmacokinetics and Safety of PF-06700841 After Single and Multiple Oral Doses as Modified Release Formulations
NCT04580797
Study of Lorlatinib In People With ALK-positive Non-small Cell Lung Cancer
NCT04362072
A Dose-Ranging Study With Vupanorsen (TRANSLATE-TIMI 70)
NCT04516291
Bioequivalence Study of PF-06651600 Capsules Relative to Tablets and Estimation of Food Effect on Capsules.
NCT04390776
Study of PF-07265807 in Participants With Metastatic Solid Tumors.
NCT04458259
A Study to Determine the Bioequivalence of Two Doses of Tafamidis
NCT04575116
Placebo-controlled Safety Study OF Ritlecitinib (PF-06651600) IN Adults With Alopecia Areata
NCT04517864
First-In-Human Study To Evaluate Safety, Tolerability, And Pharmacokinetics Following Single Ascending And Multiple Ascending Doses of PF-07304814 In Hospitalized Participants With COVID-19.
NCT04535167
Safety and Immunogenicity of 20vPnC Coadministered With SIIV in Adults ≥65 Years of Age
NCT04526574
Effect Of Multiple Dose PF-06700841 On The Pharmacokinetics Of Single Dose Oral Contraceptive Steroids
NCT04267250
Study of Pharmacodynamics and Safety of DGAT2i and ACCi Coadministered in Participants With Sponsor-defined Presumed Non Alcoholic Steatohepatitis
NCT04399538
Pharmacokinetic Study of Aztreonam-Avibactam in Severe Renal Impairment
NCT04486625
Safety and Efficacy of Oral Etrasimod in Adult Participants With Moderate-to-Severe Alopecia Areata
NCT04556734
Renal Impairment Study of PF-06700841
NCT04260464
Patient Characteristics, Treatment Patterns, and Clinical Outcomes in Patients Diagnosed With HR+/HER2 Advanced/Metastatic Breast Cancer on Palbociclib + Aromatase Inhibitor (AI) Combination Therapy
NCT04394247
Long-term Safety Study of BHV-3500 (Zavegepant*) for the Acute Treatment of Migraine
NCT04408794
Study Evaluating Efficacy and Safety of Crisaborole in Adults With Stasis Dermatitis
NCT04091087
Study Evaluating the Mechanism of Action of PF-04965842 Monotherapy for Moderate-to-severe Atopic Dermatitis
NCT03915496
MenABCWY Noninferiority Study in Healthy Participants ≥10 to <26 Years of Age
NCT04440163
A Trial to Describe the Safety and Immunogenicity of MenABCWY When Administered on 2 Schedules
NCT04440176
A Study In Adult Healthy Volunteers To Asses Once Daily (QD) Dosing With The Selected Age-Appropriate Modified Release (MR) Formulations
NCT04338711
A Trial to Evaluate the Efficacy and Safety of RSVpreF in Infants Born to Women Vaccinated During Pregnancy.
NCT04424316
Metabolic Interventions to Resolve Non-alcoholic Steatohepatitis (NASH) With Fibrosis (MIRNA)
NCT04321031
A Study TO Evaluate THE Effect OF PF-06651600 ON Pharmacokinetics OF Single Dose Sumatriptan IN Healthy Participants.
NCT04355845
Study of Abrocitinib Compared With Dupilumab in Adults With Moderate to Severe Atopic Dermatitis on Background Topical Therapy
NCT04345367
20-valent Pneumococcal Conjugate Vaccine Safety Study in Healthy Infants
NCT04379713
20-valent Pneumococcal Conjugate Vaccine Safety and Immunogenicity Study of a 4-Dose Series in Healthy Infants
NCT04382326
Safety and Efficacy Trial of Zavegepant* Intranasal for Hospitalized Patients With COVID-19 Requiring Supplemental Oxygen
NCT04346615
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 703 |
| Phase 2 | 470 |
| Phase 3 | 411 |
| Phase 4 | 93 |
Therapeutic Areas
What is open in the Pfizer pipeline
106 recruiting of 1,845 indexed (6% open); 1,335 completed (72%).
Phase mix: 504 late (III/IV) vs 1,173 early (I/II) (early-phase heavy).
Top condition: Healthy (44 trials), 9 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
Pfizer: open-pipeline peers nationwide
Peers matched on 1,845 registered trials and 6% open enrollment, not the therapeutic-area sidebar.
Pfizer sits at or above the median trial volume and below the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 1,845 trials (± recruiting share)
- Memorial Sloan Kettering Cancer Center · 1,884 trials · 17% recruiting
- Stanford University · 1,744 trials · 15% recruiting
- Duke University · 1,725 trials · 11% recruiting
- University of California, San Francisco · 1,713 trials · 16% recruiting
Sponsors near 6% open enrollment (± trial volume)
- Pacira Pharmaceuticals · 6% recruiting · 88 trials
- BioDelivery Sciences International · 6% recruiting · 17 trials
- Colgate Palmolive · 6% recruiting · 51 trials
- Durham VA Medical Center · 6% recruiting · 17 trials
Related
What to do with this Pfizer page
1,845 registered trials is a research-attention snapshot, not an endorsement of Pfizer or any single study.
- 106 of Pfizer's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Healthy is the condition Pfizer studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Healthy trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. Pfizer pipeline card: 1,845 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.